Dose-escalation studies expand the therapeutic and commercial potential of Hamlet Pharma’s drug candidate Alpha1H
Dose-escalation studies have been successful in mice with bladder cancer defining an optimal dose window for Alpha1H.Thetherapeutic effect of Alpha1H increased with higher dosesand at the highest treatment dose, visible tumor tissue was no longer detected. Importantly, there was no toxicity even at the highest dose, confirming that Alpha1H can be both therapeutic and selective for the tumor, unlike many current cancer therapies. These findings open up novel possibilities to permanently remove cancer by adjusting the dose of Alpha1H administered to specific tumors and tissue sites